1 document found, page 1 of 1
Sort by
Issue Date
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in ...
Figueiredo, A; Almeida, MA; Almodovar, MT; Alves, P; Araújo, A; Araújo, D, et al.OBJECTIVE: The main aim of the study was to evaluate the efficacy and safety profile of Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, in a real world setting. METHODS: We performed a retrospective, multicentre data analysis of patients who were included in the Portuguese Nivolumab Expanded Access Program (EAP). Eligibility crite...
Date: 2019
|
Origin: Repositório do Hospital Prof. Doutor Fernando Fonseca